Table 2.
Baseline patient characteristics.
| Panel A | Panel B | |||
|---|---|---|---|---|
| Prednisone 15 mg Number = 8 | Placebo Number = 10 | Prednisone 7.5 mg Number = 18 | Placebo Number = 9 | |
| Gender, number (%) | ||||
| Female | 6 (75.0) | 5 (50.0) | 12 (66.7) | 6 (66.7) |
| Male | 2 (25.0) | 5 (50.0) | 6 (33.3) | 3 (33.3) |
| Age, years | ||||
| Mean (SD) | 61.6 (6.5) | 58.4 (12.8) | 57.9 (13.3) | 55.1 (12.8) |
| Range | 48 to 69 | 45 to 86 | 37 to 81 | 32 to 71 |
| Race, number (%) | ||||
| Asian | 0 (0.0) | 3 (30.0) | 2 (11.1) | 3 (33.3) |
| Black | 0 (0.0) | 1 (10.0) | 4 (22.1) | 0 (0.0) |
| White | 8 (100.0) | 6 (60.0) | 12 (66.7) | 6 (66.7) |
| 10MCP Trans PDA, mean (SD) | 9.48 (6.44) | 10.55 (9.54) | 8.31 (8.66) | 9.78 (7.28) |
| DAS28(CRP), mean (SD) | 5.2 (1.3) | 5.5 (1.6) | 5.3 (1.2) | 5.6 (1.8) |
| Number of tender joints, mean (SD) | 10.9 (7.4) | 13 (10.1) | 13.6 (8.6) | 18.4 (10.1) |
| Number of swollen joints, mean (SD) | 10.1 (5.4) | 12.5 (8.7) | 11.3 (5.6) | 16.3 (8.6) |
| CRP (mg/L), median (quartiles) | 8.4 (4.2-25.3) | 14.0 (3.5-37.2) | 6.9 (1.7-14.6) | 3.7 (0.7 - 11.4) |
| Patients with positive rheumatoid factora, number (%) | 6 (75.0) | 6 (60.0) | 16 (88.9) | 6 (66.7) |
In this instance, the 10MCP Trans PDA for Panel A used data from all three baseline scans. There were no statistically significant differences, P >0.05, between groups based on nonparametric Wilcoxon and t-tests. aPositive rheumatoid factor was defined as rheumatoid factor >= 12 KU/L, the reference range for Quest assay. CRP, C-reactive protein; DAS28, Disease Activity Score in 28 Joints; MCP, metacarpophalangeal joint; PDA; Power Doppler Area; SD, standard deviation.